Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
Apogee Therapeutics (Nasdaq: APGE) announced a proposed underwritten public offering of $300 million of common stock on March 23, 2026, with a 30‑day option for underwriters to purchase up to an additional $45 million.
Net proceeds are intended to fund preclinical and clinical programs, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes. The offering is subject to market conditions and will be made by prospectus supplement under an existing registration statement.
Apogee Therapeutics (Nasdaq: APGE) reported positive 52-week Phase 2 Part A results for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The study showed durable maintenance and deepening of responses with both 3-month and 6-month maintenance dosing, and a safety profile consistent with the class.
Key metrics: EASI-75 maintenance of 75% (3-month) and 85% (6-month) and vIGA 0/1 maintenance of 86% (3-month) and 78% (6-month) among Week 16 responders. Part B 16-week induction data expected 2Q 2026; Phase 3 initiation planned for 2H 2026, with potential launch in 2029, subject to outcomes.
Apogee Therapeutics (NASDAQ: APGE) will report Part A 52-week results from the Phase 2 APEX trial of zumilokibart (APG777) on Monday, March 23, 2026. Following the announcement, the company will host a conference call and live webcast at 8:00 a.m. ET.
According to the company, the live webcast will be accessible via the Investors section on the company website and a replay will be available after the call.
Apogee Therapeutics (NASDAQ: APGE) reported full‑year 2025 results and pipeline progress, highlighting advancing clinical programs for zumilokibart (APG777) and combination candidates.
Key points: APEX Phase 2 Part A 52‑week maintenance readout expected March 2026; Part B 16‑week readout in Q2 2026; Phase 3 initiation targeted 2H 2026. Cash was $902.9M at year‑end, providing runway into 2H 2028. Positive Phase 1b asthma data and a head‑to‑head APG279 vs DUPIXENT study readout expected 2H 2026.
Apogee Therapeutics (Nasdaq: APGE) announced management will participate in three investor events in early March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and attendance at the UBS Biotech Summit Miami (March 9) and Jefferies Biotech on the Beach Summit (March 10). A live and archived webcast of the March 3 fireside chat will be available on the company’s Investors News & Events page.
Apogee Therapeutics (Nasdaq: APGE) said company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 p.m. ET.
A live and archived webcast will be available via the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1b results for zumilokibart (APG777) in 19 adults with mild-to-moderate asthma, showing a maximum mean FeNO reduction of 45 ppb (60% from baseline) after one 720 mg dose and durable FeNO suppression through 16 weeks (and through 32 weeks for patients with follow-up).
Zumilokibart was well tolerated with no Grade 3+ TEAEs, no conjunctivitis, injection-site reactions, or ADAs. Company highlights expected 2026 milestones: APEX Part A 52-week data in Q1 2026, Part B 16-week induction data in Q2 2026 (Part B enrolled 347 patients), potential Phase 3 start in 2H 2026, and a potential commercial launch in 2029. Cash of $913 million provides runway into 2H 2028.
Apogee Therapeutics (Nasdaq: APGE) will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026.
The company will host a conference call and live webcast on January 6, 2026 at 8:00 a.m. ET to discuss the interim data. The live webcast can be accessed via the company’s investor website at https://investors.apogeetherapeutics.com/news-events/events and a replay will be available after the call.
Apogee Therapeutics (NASDAQ: APGE) reported Q3 2025 results and pipeline progress on Nov 10, 2025. The company expects four clinical readouts in 2026 including APG777 Phase 1b in asthma (Q1 2026), APEX 52-week Part A maintenance data in AD (Q1 2026), APEX 16-week Part B in AD (Q2 2026), and an APG279 head-to-head interim readout vs DUPIXENT in 2H 2026.
Interim Phase 1 data for APG333 showed a ~55-day half-life, biomarker suppression to six months and support for quarterly or less frequent dosing in combination APG273. The company completed a $345M offering, with pro forma cash of $913M as of Sept 30, 2025, supporting runway into 2H 2028. Q3 operating metrics: R&D $54.2M, G&A $17.1M, net loss $65.0M.
Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1 results for APG333, a half-life–extended TSLP antibody, from a first‑in‑human, single‑ascending dose study in 32 healthy volunteers on Nov 10, 2025. Key findings: an optimized PK profile with an approximate 55‑day half‑life, durable suppression of eosinophils and IL‑5 out to 6 months after one dose, and tolerability up to 1,000 mg. Results support potential 3‑ to 6‑month dosing and development of a quarterly co‑formulation with APG777 (APG273).